60 Degrees Pharmaceuticals, Inc. (SXTP)
NASDAQ: SXTP · Real-Time Price · USD
1.600
-0.020 (-1.23%)
At close: Apr 28, 2026, 4:00 PM EDT
1.630
+0.030 (1.85%)
After-hours: Apr 28, 2026, 5:30 PM EDT
SXTP Employees
60 Degrees Pharmaceuticals had 3 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
3
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$469,698
Profits / Employee
-$2,622,071
Market Cap
4.25M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3 | 0 | - |
| Dec 31, 2024 | 3 | 0 | - |
| Dec 31, 2023 | 3 | 1 | 50.00% |
| Dec 31, 2022 | 2 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| AIM ImmunoTech | 21 |
| VivoSim Labs | 14 |
| Ensysce Biosciences | 10 |
| Revelation Biosciences | 9 |
| Dermata Therapeutics | 9 |
| Artelo Biosciences | 7 |
| Alzamend Neuro | 6 |
| Galmed Pharmaceuticals | 6 |
SXTP News
- 12 days ago - 60 Degrees Pharmaceuticals Transcript: Biotech Resurgence: Platforms and Pipelines of Today's Innovators - Transcripts
- 4 weeks ago - 60 Degrees Pharmaceuticals Announces 2025 Annual Results - GlobeNewsWire
- 5 weeks ago - 60 Degrees Pharmaceuticals Files New Dietary Ingredient Notification (NDIN) with FDA for Australian Chestnut Extract - GlobeNewsWire
- 6 weeks ago - What's Going On With 60 Degrees Pharmaceuticals On Friday? - Benzinga
- 6 weeks ago - 60 Degrees Pharmaceuticals Announces All Patients Cured of Babesiosis After Tafenoquine Treatment in Expanded Use Clinical Trial - GlobeNewsWire
- 3 months ago - 60 Degrees Pharmaceuticals Expands Access to ARAKODA® with GoodRx Partnership - GlobeNewsWire
- 3 months ago - 60 Degrees Pharmaceuticals, Inc. Announces Approval of Reverse Stock Split Ratio - GlobeNewsWire
- 4 months ago - 60 Degrees Pharmaceuticals Announces Detection of Babesia Infection in 24 Percent of Patients Presenting with Chronic Fatigue in Peer-Reviewed, Sponsored Study at NC State - GlobeNewsWire